首页 > 最新文献

Current Opinion in Nephrology and Hypertension最新文献

英文 中文
The boundaries of normal kidney tissue for biomedical research. 生物医学研究中正常肾组织的边界。
IF 2.4 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-03-10 DOI: 10.1097/MNH.0000000000001069
Jeffrey B Hodgin, Rajasree Menon, Markus Bitzer

Purpose of review: In this review, we highlight the importance of understanding the inherent biological variability in normal kidney, or healthy reference tissue, to establish an accurate reference point for biomedical research. We explore this and the advantages and limitations of various sources of healthy reference tissue suitable for structural and omics-level studies.

Recent findings: Several large consortia are employing omic technologies for diseased and normal kidney tissue, underscoring the importance of utilizing healthy reference tissue in these studies. Emerging approaches, such as artificial intelligence and multiomic analyses, are expanding our understanding of structural and molecular heterogeneity in healthy reference kidney tissue and uncovering new insights.

Summary: Biological variability in healthy reference tissue at the functional, structural, and molecular level is complex and remains an active area of study. Thoughtful selection of healthy reference tissue sources is critical, providing the greatest potential for producing high-quality research outcomes.

综述目的:在这篇综述中,我们强调了解正常肾脏或健康参考组织固有的生物学变异性的重要性,以建立生物医学研究的准确参考点。我们探讨了这一点,以及适合于结构和组学水平研究的各种健康参考组织来源的优点和局限性。最近的研究发现:一些大型财团正在使用组学技术研究病变和正常肾脏组织,强调在这些研究中使用健康参比组织的重要性。新兴的方法,如人工智能和多组学分析,正在扩大我们对健康参考肾组织的结构和分子异质性的理解,并发现新的见解。摘要:健康参考组织在功能、结构和分子水平上的生物学变异性是复杂的,仍然是一个活跃的研究领域。经过深思熟虑的健康参考组织来源的选择是至关重要的,为产生高质量的研究成果提供了最大的潜力。
{"title":"The boundaries of normal kidney tissue for biomedical research.","authors":"Jeffrey B Hodgin, Rajasree Menon, Markus Bitzer","doi":"10.1097/MNH.0000000000001069","DOIUrl":"10.1097/MNH.0000000000001069","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we highlight the importance of understanding the inherent biological variability in normal kidney, or healthy reference tissue, to establish an accurate reference point for biomedical research. We explore this and the advantages and limitations of various sources of healthy reference tissue suitable for structural and omics-level studies.</p><p><strong>Recent findings: </strong>Several large consortia are employing omic technologies for diseased and normal kidney tissue, underscoring the importance of utilizing healthy reference tissue in these studies. Emerging approaches, such as artificial intelligence and multiomic analyses, are expanding our understanding of structural and molecular heterogeneity in healthy reference kidney tissue and uncovering new insights.</p><p><strong>Summary: </strong>Biological variability in healthy reference tissue at the functional, structural, and molecular level is complex and remains an active area of study. Thoughtful selection of healthy reference tissue sources is critical, providing the greatest potential for producing high-quality research outcomes.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"218-223"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic dysfunction associated steatotic liver and kidney stones: what is going on? 代谢功能障碍相关的脂肪肝和肾结石:是怎么回事?
IF 2.4 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-01-30 DOI: 10.1097/MNH.0000000000001062
Owen P Cunneely, Anne Roberts, Sonia Fargue, John Knight, Dean G Assimos, Kyle D Wood

Purpose of review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review of the associations and possible interconnections between these two common disease processes.

Recent findings: Epidemiological studies are discordant regarding the impact of sex on this association and on the impact of MASLD on incident stone risk. The nature of kidney stones is rarely taken into account.A favorable milieu for uric acid kidney stone formation may be created by a lower urine pH resulting from defective ammonium production associated with insulin resistance, common in MASLD.Endogenous oxalate synthesis, a major risk factor for calcium oxalate kidney stones, may be increased in MASLD via decline in the activity of enzymes involved in the detoxification of glyoxylate, the immediate precursor of oxalate.

Summary: The nature of kidney stones associated with MASLD and factors driving this association remain to be elucidated. Potential mechanisms identified underlying this include an increase in the risk factors for both uric acid and calcium oxalate kidney stones.

综述目的:代谢功能障碍相关的脂肪变性肝病(MASLD)在世界范围内正在增加,影响近三分之一的人。肾结石疾病也在增加,与MASLD有关。包括肥胖、糖尿病、血脂异常、高血压和代谢综合征在内的两种常见危险因素可能是这种关联的驱动因素。我们在此综述了这两种常见疾病过程之间的关联和可能的相互联系。最近的发现:流行病学研究在性别对这种关联的影响和MASLD对事件结石风险的影响方面并不一致。人们很少考虑肾结石的性质。尿酸肾结石形成的有利环境可能是由与胰岛素抵抗相关的氨生成缺陷引起的尿pH值降低造成的,这在MASLD中很常见。内源性草酸盐合成是草酸钙肾结石的主要危险因素,在MASLD中可能通过参与草酸盐(草酸的直接前体)解毒的酶活性下降而增加。总结:肾结石与MASLD相关的性质和驱动这种关联的因素仍有待阐明。已确定的潜在机制包括尿酸和草酸钙肾结石的风险因素增加。
{"title":"Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?","authors":"Owen P Cunneely, Anne Roberts, Sonia Fargue, John Knight, Dean G Assimos, Kyle D Wood","doi":"10.1097/MNH.0000000000001062","DOIUrl":"10.1097/MNH.0000000000001062","url":null,"abstract":"<p><strong>Purpose of review: </strong>Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review of the associations and possible interconnections between these two common disease processes.</p><p><strong>Recent findings: </strong>Epidemiological studies are discordant regarding the impact of sex on this association and on the impact of MASLD on incident stone risk. The nature of kidney stones is rarely taken into account.A favorable milieu for uric acid kidney stone formation may be created by a lower urine pH resulting from defective ammonium production associated with insulin resistance, common in MASLD.Endogenous oxalate synthesis, a major risk factor for calcium oxalate kidney stones, may be increased in MASLD via decline in the activity of enzymes involved in the detoxification of glyoxylate, the immediate precursor of oxalate.</p><p><strong>Summary: </strong>The nature of kidney stones associated with MASLD and factors driving this association remain to be elucidated. Potential mechanisms identified underlying this include an increase in the risk factors for both uric acid and calcium oxalate kidney stones.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"247-253"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12679644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors. 针对醛固酮改善心肾功能:从非类固醇矿皮质激素受体拮抗剂到醛固酮合成酶抑制剂。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1097/MNH.0000000000001067
Wryan Helmeczi, Gregory L Hundemer

Purpose of review: Aldosterone dysregulation plays a major role in the pathogenesis of hypertension, cardiovascular disease, and kidney disease. Traditionally, steroidal mineralocorticoid receptor (MR) antagonists, namely spironolactone and eplerenone, have been the only available options to target aldosterone. Over recent years, a host of promising novel aldosterone-targeted pharmacologic agents have been developed thereby providing new options to mitigate aldosterone-mediated cardiovascular and kidney disease.

Recent findings: Recently, a number of nonsteroidal MR antagonists (finerenone, esaxerenone, and ocedurenone) and highly specific aldosterone synthase inhibitors (baxdrostat, lorundrostat, dexfadrostat, and vicadrostat) have been developed. The early clinical data for these novel medications looks promising regarding their efficacy in improving blood pressure control, preventing adverse cardiovascular outcomes, and slowing chronic kidney disease progression. Moreover, they appear to be generally safe and well tolerated.

Summary: In the coming years, nonsteroidal MR antagonists and aldosterone synthase inhibitors are likely to play an increasingly large role in routine medical practice to help improve cardiovascular and kidney outcomes.

综述目的:醛固酮失调在高血压、心血管疾病和肾脏疾病的发病机制中起重要作用。传统上,甾体矿物皮质激素受体(MR)拮抗剂,即螺内酯和依普利酮,是针对醛固酮的唯一可用选择。近年来,许多有前景的新型醛固酮靶向药物被开发出来,从而为减轻醛固酮介导的心血管和肾脏疾病提供了新的选择。最近的发现:最近,一些非甾体类MR拮抗剂(芬尼酮、艾塞芬酮和舒克都酮)和高度特异性的醛固酮合成酶抑制剂(巴司他、洛诺他、右法他和维卡他)已经被开发出来。这些新型药物的早期临床数据在改善血压控制、预防心血管不良后果和减缓慢性肾脏疾病进展方面看起来很有希望。此外,它们似乎总体上是安全且耐受性良好的。总结:在未来几年,非甾体MR拮抗剂和醛固酮合成酶抑制剂可能在常规医疗实践中发挥越来越大的作用,以帮助改善心血管和肾脏预后。
{"title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors.","authors":"Wryan Helmeczi, Gregory L Hundemer","doi":"10.1097/MNH.0000000000001067","DOIUrl":"10.1097/MNH.0000000000001067","url":null,"abstract":"<p><strong>Purpose of review: </strong>Aldosterone dysregulation plays a major role in the pathogenesis of hypertension, cardiovascular disease, and kidney disease. Traditionally, steroidal mineralocorticoid receptor (MR) antagonists, namely spironolactone and eplerenone, have been the only available options to target aldosterone. Over recent years, a host of promising novel aldosterone-targeted pharmacologic agents have been developed thereby providing new options to mitigate aldosterone-mediated cardiovascular and kidney disease.</p><p><strong>Recent findings: </strong>Recently, a number of nonsteroidal MR antagonists (finerenone, esaxerenone, and ocedurenone) and highly specific aldosterone synthase inhibitors (baxdrostat, lorundrostat, dexfadrostat, and vicadrostat) have been developed. The early clinical data for these novel medications looks promising regarding their efficacy in improving blood pressure control, preventing adverse cardiovascular outcomes, and slowing chronic kidney disease progression. Moreover, they appear to be generally safe and well tolerated.</p><p><strong>Summary: </strong>In the coming years, nonsteroidal MR antagonists and aldosterone synthase inhibitors are likely to play an increasingly large role in routine medical practice to help improve cardiovascular and kidney outcomes.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"241-246"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
APOL1-associated kidney disease: modulators of the genotype-phenotype relationship. apol1相关肾脏疾病:基因型-表型关系的调节因子
IF 2.4 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1097/MNH.0000000000001068
Martin R Pollak, David J Friedman

Purpose of review: Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity.

Recent findings: Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19. Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance. Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis. Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways.

Summary: These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers. Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.

载脂蛋白l1 (APOL1) G1和G2风险变异,在撒哈拉以南非洲西部人群中发现,显著增加肾脏疾病的可能性,但不完全外显率和多样化的临床表现强调需要了解调节APOL1介导的毒性的分子和环境因素。最近的发现:最近的研究证实,风险变异会产生毒性的功能获得效应,这种效应会因艾滋病毒感染和COVID-19等炎症触发因素而加剧。表观遗传机制和microRNA通路进一步调节APOL1表达,影响疾病外显率。多种模型已经阐明了亚细胞定位、信号肽加工以及与内质网的相互作用可能有助于发病机制。治疗进展包括靶向APOL1离子通道活性的抑制剂和阻断关键炎症信号通路的策略。总结:这些发现强调了一个由APOL1变异的内在毒性潜力和许多外在触发因素驱动的多方面疾病过程。了解这种复杂的相互作用对于风险分层和精确治疗的发展至关重要,可能会改善受apol1相关肾脏疾病不成比例影响的人群的预后。
{"title":"APOL1-associated kidney disease: modulators of the genotype-phenotype relationship.","authors":"Martin R Pollak, David J Friedman","doi":"10.1097/MNH.0000000000001068","DOIUrl":"10.1097/MNH.0000000000001068","url":null,"abstract":"<p><strong>Purpose of review: </strong>Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity.</p><p><strong>Recent findings: </strong>Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19. Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance. Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis. Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways.</p><p><strong>Summary: </strong>These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers. Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"191-198"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of intensive blood pressure control on kidney outcomes. 强化血压控制对肾脏预后的影响。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-03-07 DOI: 10.1097/MNH.0000000000001070
Jia Xin Huang, Vanessa-Giselle Peschard, Elaine Ku

Purpose of review: Hypertension has long been recognized as a modifiable risk factor for cardiovascular events. However, the role of intensive blood pressure (BP) control in preventing kidney disease progression continues to be debated. This review will provide a brief update on the evidence in support of or against the intensive control of BP on kidney outcomes in patient with chronic kidney disease (CKD), focusing particularly on trial-grade evidence.

Recent findings: Recently, three large trials conducted in China compared the effects of intensive BP control in adults with cardiovascular risk factors. All three trials demonstrated that intensive BP control confers cardiovascular benefits, but mixed results were noted in terms of the risk of adverse kidney outcomes. In individual-level meta-analyses of six trials of different BP control strategies in patients with CKD, intensive BP control appeared to reduce the risk of kidney replacement therapy in those with CKD stage 4-5, but not in patients with CKD stage 3.

Summary: Most guidelines continue to recommend a systolic BP target of 120-130 mmHg for patients with CKD given the cardiovascular benefits observed in trials of intensive BP control, though there are some signals of potential risks to the kidney with this BP treatment strategy.

综述目的:高血压一直被认为是心血管事件的可改变危险因素。然而,强化血压(BP)控制在预防肾脏疾病进展中的作用仍存在争议。本综述将简要介绍支持或反对强化血压控制对慢性肾脏疾病(CKD)患者肾脏预后影响的最新证据,尤其侧重于试验级证据。最近的发现:最近,在中国进行的三个大型试验比较了强化血压控制对心血管危险因素的成年人的影响。所有三项试验都表明,强化血压控制对心血管有益,但在肾脏不良结局的风险方面,结果好坏参半。在对CKD患者不同血压控制策略的六项试验的个体水平荟萃分析中,强化血压控制似乎可以降低CKD 4-5期患者肾脏替代治疗的风险,但在CKD 3期患者中没有。总结:大多数指南继续推荐CKD患者的收缩压目标为120-130 mmHg,因为在强化血压控制的试验中观察到心血管方面的益处,尽管有一些信号表明这种血压治疗策略对肾脏有潜在风险。
{"title":"Impact of intensive blood pressure control on kidney outcomes.","authors":"Jia Xin Huang, Vanessa-Giselle Peschard, Elaine Ku","doi":"10.1097/MNH.0000000000001070","DOIUrl":"10.1097/MNH.0000000000001070","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypertension has long been recognized as a modifiable risk factor for cardiovascular events. However, the role of intensive blood pressure (BP) control in preventing kidney disease progression continues to be debated. This review will provide a brief update on the evidence in support of or against the intensive control of BP on kidney outcomes in patient with chronic kidney disease (CKD), focusing particularly on trial-grade evidence.</p><p><strong>Recent findings: </strong>Recently, three large trials conducted in China compared the effects of intensive BP control in adults with cardiovascular risk factors. All three trials demonstrated that intensive BP control confers cardiovascular benefits, but mixed results were noted in terms of the risk of adverse kidney outcomes. In individual-level meta-analyses of six trials of different BP control strategies in patients with CKD, intensive BP control appeared to reduce the risk of kidney replacement therapy in those with CKD stage 4-5, but not in patients with CKD stage 3.</p><p><strong>Summary: </strong>Most guidelines continue to recommend a systolic BP target of 120-130 mmHg for patients with CKD given the cardiovascular benefits observed in trials of intensive BP control, though there are some signals of potential risks to the kidney with this BP treatment strategy.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"224-231"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-03-27 DOI: 10.1097/MNH.0000000000001071
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MNH.0000000000001071","DOIUrl":"https://doi.org/10.1097/MNH.0000000000001071","url":null,"abstract":"","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":"34 3","pages":"v"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond. 胰高血糖素样肽-1受体激动剂改善心肾预后:来自FLOW及其他的数据。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1097/MNH.0000000000001066
Labib Faruque, Kevin Yau, David Z I Cherney

Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP1RA), initially approved for glycemic control in type 2 diabetes mellitus (T2DM), have emerged as agents for weight loss, cardiovascular and kidney protection. This review summarizes the evidence supporting the benefits of these therapies on cardiorenal outcomes.

Recent findings: Clinical trials have consistently demonstrated reductions in major adverse cardiovascular events with GLP1RA treatments. Recently, the FLOW trial revealed that semaglutide reduced the composite outcome of kidney failure, at least 50% decline in estimated glomerular filtration rate, kidney or cardiovascular mortality by 24% in patients with T2DM, thereby establishing GLP1RA as a pillar of therapy in this population. New evidence suggests favorable effects on kidney endpoints in nondiabetic individuals with overweight or obesity. Dedicated trials have also provided evidence for reduction in the risk for heart failure hospitalization and improvement in symptoms in individuals with heart failure with preserved ejection fraction. Subgroup analyses have suggested that GLP1RAs confer additive cardiorenal benefits irrespective of background medication use.

Summary: There is increasing evidence that GLP1RA reduces the risk for cardiovascular events, chronic kidney disease progression, and heart failure hospitalizations. Further data on the effect of dual and triple GLP1-based therapies on cardiorenal outcomes is required.

综述目的:胰高血糖素样肽-1受体激动剂(GLP1RA)最初被批准用于2型糖尿病(T2DM)的血糖控制,现已成为减肥、心血管和肾脏保护的药物。这篇综述总结了支持这些疗法对心肾预后的益处的证据。最新发现:临床试验一致表明,GLP1RA治疗可减少主要不良心血管事件。最近,FLOW试验显示,西马鲁肽降低了肾衰竭的综合结局,估计肾小球滤过率降低至少50%,T2DM患者的肾脏或心血管死亡率降低24%,从而确立了GLP1RA作为该人群治疗的支柱。新的证据表明,超重或肥胖的非糖尿病患者对肾脏终点有利。专门的试验也提供了证据,可以降低心力衰竭住院的风险,并改善保留射血分数的心力衰竭患者的症状。亚组分析表明,GLP1RAs与背景药物使用无关,可赋予附加的心肾益处。总结:越来越多的证据表明,GLP1RA可降低心血管事件、慢性肾脏疾病进展和心力衰竭住院的风险。需要更多关于双重和三重glp1治疗对心肾预后影响的数据。
{"title":"Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond.","authors":"Labib Faruque, Kevin Yau, David Z I Cherney","doi":"10.1097/MNH.0000000000001066","DOIUrl":"10.1097/MNH.0000000000001066","url":null,"abstract":"<p><strong>Purpose of review: </strong>Glucagon-like peptide-1 receptor agonists (GLP1RA), initially approved for glycemic control in type 2 diabetes mellitus (T2DM), have emerged as agents for weight loss, cardiovascular and kidney protection. This review summarizes the evidence supporting the benefits of these therapies on cardiorenal outcomes.</p><p><strong>Recent findings: </strong>Clinical trials have consistently demonstrated reductions in major adverse cardiovascular events with GLP1RA treatments. Recently, the FLOW trial revealed that semaglutide reduced the composite outcome of kidney failure, at least 50% decline in estimated glomerular filtration rate, kidney or cardiovascular mortality by 24% in patients with T2DM, thereby establishing GLP1RA as a pillar of therapy in this population. New evidence suggests favorable effects on kidney endpoints in nondiabetic individuals with overweight or obesity. Dedicated trials have also provided evidence for reduction in the risk for heart failure hospitalization and improvement in symptoms in individuals with heart failure with preserved ejection fraction. Subgroup analyses have suggested that GLP1RAs confer additive cardiorenal benefits irrespective of background medication use.</p><p><strong>Summary: </strong>There is increasing evidence that GLP1RA reduces the risk for cardiovascular events, chronic kidney disease progression, and heart failure hospitalizations. Further data on the effect of dual and triple GLP1-based therapies on cardiorenal outcomes is required.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"232-240"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking arterial hypertension: the need for a paradigm shift. 重新思考动脉高血压:需要一个范式转变。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI: 10.1097/MNH.0000000000001065
Gian Paolo Rossi, Domenico Bagordo, Federico Bernardo Rossi

Purpose of review: Essential (primary or idiopathic) hypertension is presented as the most prevalent 'cause' of arterial hypertension, which is a paradoxical statement for a condition whose causes are unknown. The consequence of this description is that secondary hypertension is held to be exceptional and, therefore, very rarely sought for in current clinical practice. Labelling a hypertensive patient as 'essential' means that no further investigations will be undertaken to discover the cause of hypertension, therefore neglecting the possibility of long-term cure of hypertension and sentencing the patient to a life-long drug treatment.

Recent findings: We will describe how the notion of essential hypertension has developed and whether scientific evidence from the most recent studies still support the conclusion that it is highly prevalent. The concept of secondary hypertension along with the criteria to be used to define it as such are also being examined.

Summary: The evidence that secondary hypertension is highly prevalent, when systematically sought for, should increase the awareness of this condition and lead to a broader search for it, which are fundamental steps to achieve cure or a better control of high blood pressure, thus improving patients' outcome and quality of life.

回顾的目的:本质性(原发性或特发性)高血压被认为是动脉高血压最普遍的 "病因",这对于一种病因不明的疾病来说是一种自相矛盾的说法。这种说法的后果是,继发性高血压被认为是一种特殊情况,因此在目前的临床实践中很少被发现。给高血压患者贴上 "原发性 "标签意味着不再进行进一步的检查以发现高血压的病因,从而忽视了长期治愈高血压的可能性,并使患者终生接受药物治疗:我们将介绍本质高血压这一概念是如何发展起来的,以及最新研究的科学证据是否仍然支持本质高血压非常普遍这一结论。小结:有证据表明继发性高血压的发病率很高,如果能系统地寻找继发性高血压,就能提高人们对这种疾病的认识,并引导人们更广泛地寻找继发性高血压,这是治愈或更好地控制高血压的基本步骤,从而改善患者的预后和生活质量。
{"title":"Rethinking arterial hypertension: the need for a paradigm shift.","authors":"Gian Paolo Rossi, Domenico Bagordo, Federico Bernardo Rossi","doi":"10.1097/MNH.0000000000001065","DOIUrl":"10.1097/MNH.0000000000001065","url":null,"abstract":"<p><strong>Purpose of review: </strong>Essential (primary or idiopathic) hypertension is presented as the most prevalent 'cause' of arterial hypertension, which is a paradoxical statement for a condition whose causes are unknown. The consequence of this description is that secondary hypertension is held to be exceptional and, therefore, very rarely sought for in current clinical practice. Labelling a hypertensive patient as 'essential' means that no further investigations will be undertaken to discover the cause of hypertension, therefore neglecting the possibility of long-term cure of hypertension and sentencing the patient to a life-long drug treatment.</p><p><strong>Recent findings: </strong>We will describe how the notion of essential hypertension has developed and whether scientific evidence from the most recent studies still support the conclusion that it is highly prevalent. The concept of secondary hypertension along with the criteria to be used to define it as such are also being examined.</p><p><strong>Summary: </strong>The evidence that secondary hypertension is highly prevalent, when systematically sought for, should increase the awareness of this condition and lead to a broader search for it, which are fundamental steps to achieve cure or a better control of high blood pressure, thus improving patients' outcome and quality of life.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":"34 3","pages":"259-266"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The kidney under heat stress: a vulnerable state. 热应激下的肾脏:一种脆弱的状态。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-03-01 Epub Date: 2024-12-13 DOI: 10.1097/MNH.0000000000001050
Fabiano Amorim, Zachary Schlader

Purpose of review: This review examines the effects of occupational heat stress on kidney health. It focuses on the role of hyperthermia in the development of acute kidney injury (AKI) and its potential progression to chronic kidney disease of nontraditional etiology (CKDnt). We highlight the physiological mechanisms by which hyperthermia affects kidney function and discuss emerging preventive strategies.

Recent findings: Hyperthermia places the kidneys in a vulnerable state. As body temperature increases, blood flow is directed toward the skin to aid in cooling, diverting it away from internal organs like the kidneys to support blood pressure regulation. At the same time, hyperthermia and dehydration increases energetic demand to promote fluid and electrolyte conservation. Collectively, this can create a localized supply-demand mismatch, resulting in tissue hypoxia that can damage kidney tissues. These findings highlight that heat hyperthermia can lead to subclinical kidney damage, with potential long-term implications for kidney health.

Summary: Heat-induced AKI is a growing public health concern. Individuals engaged in manual labor with prolonged exposure are at risk of CKDnt. Interventions aimed to prevent hyperthermia show promise in mitigating the risk of AKI. Further research is necessary to refine these strategies and establish evidence-based guidelines for reducing heat-related kidney injuries.

综述目的:本综述探讨了职业性热应激对肾脏健康的影响。它侧重于热疗在急性肾损伤(AKI)发展中的作用及其发展为非传统病因的慢性肾脏疾病(CKDnt)的潜在进展。我们强调了热疗影响肾功能的生理机制,并讨论了新兴的预防策略。最近的研究发现:高温使肾脏处于脆弱状态。随着体温的升高,血液流向皮肤以帮助降温,将血液从肾脏等内部器官转移出去,以支持血压调节。同时,高温和脱水会增加能量需求,以促进液体和电解质的保存。总的来说,这会造成局部的供需不匹配,导致组织缺氧,从而损害肾脏组织。这些发现强调,热疗可导致亚临床肾损伤,对肾脏健康具有潜在的长期影响。摘要:热致AKI是一个日益严重的公共卫生问题。长期从事体力劳动的人有CKDnt的风险。旨在预防热疗的干预措施有望降低AKI的风险。进一步的研究需要完善这些策略,并建立基于证据的指南,以减少热相关的肾损伤。
{"title":"The kidney under heat stress: a vulnerable state.","authors":"Fabiano Amorim, Zachary Schlader","doi":"10.1097/MNH.0000000000001050","DOIUrl":"10.1097/MNH.0000000000001050","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review examines the effects of occupational heat stress on kidney health. It focuses on the role of hyperthermia in the development of acute kidney injury (AKI) and its potential progression to chronic kidney disease of nontraditional etiology (CKDnt). We highlight the physiological mechanisms by which hyperthermia affects kidney function and discuss emerging preventive strategies.</p><p><strong>Recent findings: </strong>Hyperthermia places the kidneys in a vulnerable state. As body temperature increases, blood flow is directed toward the skin to aid in cooling, diverting it away from internal organs like the kidneys to support blood pressure regulation. At the same time, hyperthermia and dehydration increases energetic demand to promote fluid and electrolyte conservation. Collectively, this can create a localized supply-demand mismatch, resulting in tissue hypoxia that can damage kidney tissues. These findings highlight that heat hyperthermia can lead to subclinical kidney damage, with potential long-term implications for kidney health.</p><p><strong>Summary: </strong>Heat-induced AKI is a growing public health concern. Individuals engaged in manual labor with prolonged exposure are at risk of CKDnt. Interventions aimed to prevent hyperthermia show promise in mitigating the risk of AKI. Further research is necessary to refine these strategies and establish evidence-based guidelines for reducing heat-related kidney injuries.</p>","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":" ","pages":"170-176"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introduction. 编辑介绍。
IF 2.2 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1097/MNH.0000000000001059
{"title":"Editorial introduction.","authors":"","doi":"10.1097/MNH.0000000000001059","DOIUrl":"https://doi.org/10.1097/MNH.0000000000001059","url":null,"abstract":"","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":"34 2","pages":"v"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Nephrology and Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1